Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 6, 2006, Pages 581-589

  Yu, Hui Min ^a,b   Lin, Shu Guang ^a,b   Liu, Guo Zhang ^a,b   Zhang, Yu Qing ^a,b   Ma, Wen Jun ^a,b   Deng, Chun Yu ^a,b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; RESTRICTION ENDONUCLEASE; THYMIDINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ALDOSTERONE SYNTHASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; BLOOD PRESSURE; CHINA; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLIDINES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 33744816503     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.02.007     Document Type: Article

References (28)

1. Bidiville J., Nussberger J., Waeber G., Porchet M., Waeber B., and Brunner H.R. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 11 (1988) 166-173
2. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA 165 (1957) 835-837
3. Inoue I., Nakajima T., Williams C.S., Quackenbush J., Puryear R., Powers M., et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99 (1997) 1786-1797
4. Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E., and Brown M.J. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 13 (1995) 1602-1609
5. Sethi A.A., Nordestgaard B.G., and Tybjærg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease. a meta-analysis. Arterioscler Thromb Vasc Biol 23 (2003) 1269-1275
6. Kikuya M., Sugimoto K., Katsuya T., Suzuki M., Sato T., Funahashi J., et al. A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure. the Ohasama Study. Hypertens Res 26 (2003) 141-145
7. White P.C. Disorders of aldosterone biosynthesis and action. N Engl J Med 331 (1994) 250-258
8. Clyne C.D., Zhang Y., Slutsker L., Mathis J.M., White P.C., and Rainey W.E. Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol 11 (1997) 638-649
9. Kumar N.N., Benjafield A.V., Lin R.C.Y., Wang W.Y.S., Stowasser M., and Morris B.J. Haplotype analysis of aldosterone synthase gene CYP11B2 polymorphisms shows association with essential hypertension. J Hypertens 21 (2003) 1331-1337
10. Nicod J., Bruhin D., Auer L., Vogt B., Frey F.J., and Ferrari P. A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab 88 (2003) 2495-2500
11. Pesole G., Liuni S., Grillo G., Licciulli F., Mignone F., Gissi C., et al. UTRdb and UTRsite. specialized databases of sequences and functional elements of 5' and 3' untranslated regions of eukaryotic mRNAs. Update 2002. Nucleic Acids Res 30 (2002) 335-340
12. Imidapril and Benazepril Clinical Study Cooperation Unit. Comparative study of hypotensive efficacy and the cough occurrence of imidapril versus benazepril. Chin J Cardiol 32 (2004) 304-307
13. Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H., et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97 (1998) 569-575
14. Takeda Y., Furukawa K., Inaba S., Miyamori I., and Mabuchi H. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. J Clin Endocrinol Metab 84 (1999) 1633-1637
15. Paillard F., Chansel D., Brand E., Benetos A., Thomas F., Czekalski S., et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 34 (1999) 423-429
16. White P.C., and Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 21 (1995) 437-442
17. Brand E., Chatelain N., Mulatero P., Fery I., Curnow K., Jeunemaitre X., et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32 (1998) 198-204
18. Tamaki S., Iwai N., Tsujita Y., and Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 33 (1999) 266-270
19. Russo P., Siani A., Venezia A., Iacone R., Russo O., Barba G., et al. Interaction between the C(-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels. cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 20 (2002) 1785-1792
20. Lim P.O., Macdonald T.M., Holloway C., Friel E., Anderson N.H., Dow E., et al. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab 87 (2002) 4398-4402
21. Davies E., Holloway C.D., Ingram M.C., Inglis G.C., Friel E.C., Morrison C., et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33 (1999) 703-707
22. Tsujita Y., Iwai N., Katsuya T., Higaki J., Ogihara T., Tamaki S., et al. Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese. the suite study. Hypertens Res 24 (2001) 105-109
23. Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., et al. Aldosterone synthase (CYP11B2) -344C/T polymorphism is related to antihypertensive response. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA) trial. Am J Hypertens 15 (2002) 389-393
24. Ortlepp J.R., Hanrath P., Mevissen V., Kiel G., Borggrefe M., and Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 445 (2002) 151-152
25. Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Cook S., Ulick S., et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 (1992) 262-265
26. Litchfield W.R., Hunt S.C., Jeunemaitre X., Fisher N.D.L., Hopkins P.N., Williams R.R., et al. Increased urinary free cortisol. a potential intermediate phenotype of essential hypertension. Hypertension 31 (1998) 569-574
27. Keavney B., Mayosi B., Gaukrodger N., Imrie H., Baker M., Fraser R., et al. Genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. J Clin Endocrinol Metab 90 (2005) 1072-1077
28. Ganapathipillai S., Laval G., Hoffmann I.S., Castejon A.M., Nicod J., Dick B., et al. CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity. J Clin Endocrinol Metab 90 (2005) 1220-1225